Skip to main content
. 2021 Mar 25;22(1):15. doi: 10.1186/s10194-021-01230-w

Fig. 4.

Fig. 4

Estimated mean percentage of patients with ≥50%, ≥75%, and 100% reduction from baseline in monthly migraine headache days at months 1–3. * p < 0.05, ** p < 0.01, *** p ≤ 0.0001 vs placebo. SE standard error